Abstract
Introduction
High-dose insulin (HDI) therapy has been used successfully for beta-blocker toxicity, but needs further study when hypotension persists despite HDI. The objective was to develop a model of propranolol toxicity with persistent hypotension despite HDI and to develop means to measure cerebral oxygen tension (PbrO2).
Methods
Eight anesthetized Yorkshire pigs were instrumented with a tracheostomy, Swan–Ganz catheter, arterial catheter, and intra-cerebral pressure and oxygen monitor. Intravenous propranolol was given until the initial point of toxicity (POT); 25% reduction from baseline mean arterial pressure (MAP) × heart rate (HR). At the initial POT, normal saline (NS) bolus and infusion along with HDI infusion were started. The propranolol infusion was titrated up slowly to induce hypotension. Group 2 pigs received a norepinephrine (NE) infusion after a secondary POT defined as a MAP < 50 mmHg. NE was titrated to maintain subsequent MAPs > 50 mmHg. Cardiac output, HR, MAP, PbrO2, and intracranial pressure were then recorded every 5 min until death or 4 h. Systemic vascular resistance, potassium, and glucose were also measured. Surviving pigs were euthanized.
Results
Two pigs received unique doses for protocol development. One pig developed a tachyarrhythmia prior to protocol, one failed to reach secondary POT, leaving 2 pigs in each group reaching secondary POT. The range of PbrO2 recordings for group 1 was 12.7–48.5 mmHg and 9.2–26.2 mmHg for group 2.
Conclusion
We report a pilot study swine model of propranolol toxicity with hypotension despite HDI, in which physiologic measures including PbrO2 are achieved. Our toxicity model can be used in the future, and the hemodynamic and brain monitoring model may prove important for subsequent research in various contexts.
Keywords: Overdose, High-dose insulin, Pig, Licox, Brain
Introduction
Beta-blocker-induced toxicity causes significant morbidity and mortality in the USA despite recent advances in management [1]. The toxicity resulting from such ingestion is manifested as severe hypotension and bradycardia, which may lead to organ hypoperfusion, hemodynamic collapse, and eventual death. No therapy has proven universally effective. Experience with high-dose insulin demonstrates that humans respond to high-dose insulin (HDI) when other agents have failed [2]. Insulin, an inotropic agent, restores tissue perfusion via increase in cardiac output. Cases of severe poisoning may cause hypotension despite maximal HDI therapy. Vasopressors increase mean arterial pressure (MAP) but also increase afterload. Some animal models show increased mortality with vasopressor use in poison-induced cardiogenic shock (PICS) [3]. Vasopressor use may be justified when the MAP is below the lower limit of cerebral blood flow autoregulation, but the impact of vasopressors on cerebral perfusion in PICS remains unclear. Studying brain perfusion during severe poison-induced cardiac toxicity and subsequent treatment could shed light on this subject, but there is not a repeatable model allowing for this sort of study. The objective of this study was to develop a swine model of propranolol toxicity that allowed for the repeated measurement of brain tissue oxygenation (PbtO2) in addition to hemodynamic monitoring in the context of poison-induced cardiogenic shock.
Methods
Our study was approved and monitored independently by our institutional review board and animal care and use committee; funded was obtained through a research grant internal to our institution. The purpose of this pilot study was to develop a model for feasibility and to allow for post hoc analysis in order to power future studies. Therefore, the study length and the number of subjects were based on the researchers’ experience with similar toxicity models rather than a priori statistical powering. Interventions were not randomized and the study was not blinded. This allowed researchers to adjust the protocol in real time to achieve the final protocol and a viable model (Fig. 1).
Fig. 1.
The final protocol and the viable model achieved
Eight anesthetized adult Yorkshire pigs were instrumented with a tracheostomy, Swan–Ganz catheter, arterial catheter, and intra-cerebral pressure and oxygen monitor (Licox® and Camino®, Integra LifeSciences). After induction of anesthesia via inhaled nitrous oxide and isoflurane, peripheral intravenous (IV) access was established and a tracheostomy was placed with a standard technique. Next, after identification of surface landmarks, the scalp was reflected to expose the calvaria for placement of the bolt for the intra-cerebral monitors. The bolt was placed approximately 1 cm caudal to the frontal–parietal cranial suture and 1 cm left lateral to the sagittal cranial suture and the monitors inserted [4]. Once secured and calibrated, the brain tissue oxygenation (PbtO2) was monitored until stable readings were obtained [5]. While allowing for stabilization of PbtO2 readings, a Swan–Ganz catheter and arterial catheter were placed via a standard technique. Once PbtO2 was stable and all instruments in place, baseline measurements of hemodynamics and laboratory markers were taken, including heart rate, MAP, and PbtO2.
After instrumentation, toxicity was induced with IV propranolol. Of note, propranolol dosing initially followed previously published models from this group, but adjustments were required to achieve greater toxicity [6, 7]. Thusly, the first two pigs in our study had unique doses of propranolol titrated in order to derive the dosing protocol for the remaining six animals, four of which ultimately completed the protocol. In the animals that followed, a 0.5 mg/kg bolus of propranolol was given, then a 0.25 mg/kg/min infusion (gtt) until the initial point of toxicity (POT), defined as 25% reduction from baseline MAP × heart rate (HR). The initial POT marked the start of the resuscitation protocol. At the initial POT, a 20 ml/kg normal saline (NS) bolus was given along with a 1 ml/kg/h NS gtt and a 10 units/kg/h insulin gtt. The 20 ml/kg bolus was pushed by hand rapidly to prevent hemodynamic collapse. Pigs were divided into two groups in unblinded, nonrandom fashion to allow for guided protocol development. Group 1 pigs received IV fluids and HDI for resuscitation after the initial POT. The propranolol infusion was then set at 0.125 mg/kg/min for 60 minutes (min), then 0.1875 mg/kg/min for 30 min, and finally to 0.2188 mg/kg/min for the rest of the protocol. This empirically derived titrated dosing was utilized in lieu of the constant infusion from previous models to achieve progressive toxicity and hypotension despite HDI. A secondary POT was defined as a MAP < 50 mmHg after the resuscitation with HDI and IV fluids. After the secondary POT, pigs in group 1 received ongoing HDI only and group 2 pigs received a norepinephrine (NE) gtt in addition to HDI. The NE gtt was titrated from 0.1 to 0.3 mcg/kg/min to maintain subsequent MAPs > 50 mmHg. Cardiac output, HR, MAP, PbtO2, and intracranial pressure were recorded every 5 min from the initial POT (Table 1). Systemic vascular resistance, potassium, and glucose were also measured. Pigs surviving 4 h beyond secondary POT were euthanized.
Table 1.
Recorded cardiac output, HR, MAP, PbtO2, and intracranial pressure
| Subject ID | Weight (kg) | Cardiac output (l/min) | Heart rate | Mean arterial resistance | Systemic vascular resistance | Intracranial pressure (cm water) | Cerebral oxygen (PbtO2 mmHg) | Intervention |
|---|---|---|---|---|---|---|---|---|
| C | 39.5 | 3.5 (2.4–4.9) | 75 (69–88) | 59 (33–66) | 1143 | 16 (15–23) | 36.8 (4.7–36.8) | HDI |
| G | 42.2 | 4.5 (2.8–5.2) | 97 (65–100) | 61 (40–62) | 1013 | 15 (15–20) | 28.5 (12.3–41.7) | HDI |
| D | 37.5 | 3.2 (2.0–3.2) | 77 (59–90) | 68 (30–68) | 1500 | 17 (17–23) | 23.5 (6.8–28.3) | HDI + NE |
| E | 41.2 | 3.5 (1.7–4.2) | 96 (50–96) | 67 (35–67) | 1322 | 15 (14–21) | 20.1 (18–26.6) | HDI + NE |
HDI high-dose insulin, NE norepinephrine
PbtO2 and MAP measures were analyzed from the four pigs that completed the protocol. PbtO2 measurements for each group were plotted over time and a trend line for each group was fit to the scatter plot via simple linear regression. Pooled MAP readings across groups were divided into MAP > 50 mmHg and MAP < 50 mmHg and correlated with PbtO2.
Results
Figure 2 demonstrates the fate of the 8 subjects. Two pigs received unique dosing in order to derive the protocol and were excluded from analysis. One pig suffered an arrhythmia during instrumentation and died prior to beginning the protocol and was excluded from analysis. One pig failed to reach the secondary POT and was excluded from analysis. The remaining four pigs completed the protocol and were ultimately utilized for data analysis. Two pigs (subjects C and G, Figs. 2 and 3) completed the entire protocol in group 1 with HDI. Two pigs (subjects D and E, Figs. 2 and 3) completed the protocol in group 2 with HDI and norepinephrine after MAP was < 50 mmHg. The trend line of PbtO2 over time for group 1 is represented by PbtO2 = 25.5 mmHg − 2 .2 mmHg/h. For group 2, the trend line of PbtO2 over time is represented by PbtO2 = 24.4 mmHg − 0.51 mmHg/h (Fig. 3). The difference in slopes was estimated to be 1.69 mmHg/h. These were estimated by a linear mixed effects model, which found the interaction between treatment group and time to be statistically significant (p = 0.0005). PbtO2 correlated with pooled MAP readings across subjects when MAPs were less than 50 mmHg across subjects (r = 0.625, 0.502–0.723). When pooled MAP recordings were greater than 50 mmHg, MAP correlated poorly with PbtO2 (r = 0.050, − 0.133 to 0.229) (Fig. 4).
Fig. 2.

The fate of the 8 subjects
Fig. 3.
Cerebral O2 pressure (PbTO2) vs time from secondary toxicity
Fig. 4.
Pooled MAP readings vs PbtO2
Discussion
Data in our pilot study provide meaningful insights into hypotension from propranolol toxicity despite maximal HDI therapy. The correlation of PbtO2 and MAP when MAP is less than 50 mmHg suggests a failure of cerebral blood flow autoregulation and resulting flow-dependent cerebral perfusion. PbtO2 did not correlate with MAP when MAP is greater than 50 mmHg consistent with flow-independent cerebral perfusion and intact cerebral blood flow autoregulation. These findings are consistent with our understanding of the physiology in both humans and swine at the lower limit of autoregulation of cerebral blood flow and strengthen the applicability of our model of cerebral perfusion in PICS [8, 9]. In head-injured humans, PbtO2 values of less than 15 mmHg are associated with poor outcomes, while greater than 25 mmHg is normal [10]. Others have used swine models to study brain tissue oxygenation and perfusion in other contexts and with other monitoring techniques [4, 8, 11–14]. Our swine model provides multiple data points of PbtO2 responsive to treatment and crossing these clinically relevant thresholds in the unique setting of progressive PICS (Fig. 2). In this limited data, there is a notable difference in the change in PbtO2 over time; group 1 subjects treated with HDI have a decline of 2.2 mmHg/h while group 2 subjects treated with HDI and titrated norepinephrine have a PbtO2 decline of only 0.51 mmHg/h despite worsening PICS (Fig. 2). These data can be used to power future studies. At this preliminary state, the difference in PbtO2 over time between groups only suggests that PbtO2 is a reasonable endpoint for studying the effect of vasopressors on cerebral perfusion in the setting of PICS. Moreover, we believe this model could also be utilized and adapted to study cerebral perfusion in shock states outside of PICS.
Limitations
This is a pilot study for toxicity model development and for the development of repeatable monitoring including hemodynamic parameters and brain oxygenation. The small number of subjects makes this useful in achieving the model but not in drawing treatment conclusions. The study was not blinded and 4 of the 8 initial animals were excluded from the analysis thus further limiting the ability to draw conclusions from the results other than to help power future studies.
Conclusions
We report a novel pilot study with a swine model of propranolol toxicity resulting in hypotension despite maximal HDI therapy, which also successfully allows for repeated measure of PbtO2. This toxicity model will prove useful in subsequent research in toxin-induced hypotension and shock. The monitoring model may be extended to research in many contexts necessitating brain monitoring during hemodynamic compromise.
Acknowledgments
In memory of Kristen Engebretsen PharmD, DABAT, a great clinician, colleague, and dedicated researcher who passed away before completion of this manuscript.
Source of Funding
This study was funded by a HealthPartners Discovery Grant, a grant completely internal to the investigators’ institution; no outside funding obtained.
Compliance with Ethical Standards
Our study was approved and monitored independently by our institutional review board and animal care and use committee.
Conflicts of Interest
None.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Gummin DD, Mowry JB, Spyker DA, Brooks DE, Fraser MO, Banner W. 2016 annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 34th annual report. Clin Toxicol. 2017;55:1072–1252. doi: 10.1080/15563650.2017.1388087. [DOI] [PubMed] [Google Scholar]
- 2.Holger JS, Stellpflug SJ, Cole JB, Harris CR, Engebretsen KM. High-dose insulin: a consecutive case series in toxin-induced cardiogenic shock. Clin Toxicol. 2011;49(7):653–658. doi: 10.3109/15563650.2011.593522. [DOI] [PubMed] [Google Scholar]
- 3.Holger JS, Engebretsen KM, Fritzlar SJ, Patten LC, Harris CR, Flottemesch TJ. Insulin versus vasopressin and epinephrine to treat beta-blocker toxicity. Clin Toxicol. 2007;45(4):396–401. doi: 10.1080/15563650701285412. [DOI] [PubMed] [Google Scholar]
- 4.Manley GT, Pitts LH, Morabito D, Doyle CA, Gibson J, Gimbel M, Hopf HW, Knudson MM. Brain tissue oxygenation during hemorrhagic shock, resuscitation, and alterations in ventilation. J Trauma. 1999;46(2):261–267. doi: 10.1097/00005373-199902000-00011. [DOI] [PubMed] [Google Scholar]
- 5.Corporation IL. Integra® Licox® tunneling brain tissue oxygen and temperature monitoring kit 2010–2014 [cited 2014 Nov 20]. Available from: http://www.integralife.com/index.aspx?redir=detailproduct&Product=342&ProductName=Integra%AE Licox%AE Tunneling Brain Tissue Oxygen and Temperature Monitoring Kit&ProductLineName=Brain Tissue O2 Monitoring&ProductLineID=10&PA=neurosurgeon.
- 6.Cole JB, Stellpflug SJ, Ellsworth H, Anderson CP, Adams AB, Engebretsen KM, Holger JS. A blinded, randomized, controlled trial of three doses of high-dose insulin in poison-induced cardiogenic shock. Clin Toxicol. 2013;51(4):201–207. doi: 10.3109/15563650.2013.770152. [DOI] [PubMed] [Google Scholar]
- 7.Holger JS, Engebretsen KM, Obetz CL, Kleven TL, Harris CR. A comparison of vasopressin and glucagon in beta-blocker induced toxicity. Clin Toxicol. 2006;44(1):45–51. doi: 10.1080/15563650500394795. [DOI] [PubMed] [Google Scholar]
- 8.Lagerkranser M, Stange K, Sollevi A. Effects of propofol on cerebral blood flow, metabolism, and cerebral autoregulation in the anesthetized pig. J Neurosurg Anesthesiol. 1997;9(2):188–193. doi: 10.1097/00008506-199704000-00015. [DOI] [PubMed] [Google Scholar]
- 9.Lassen NA. Cerebral blood flow and oxygen consumption in man. Physiol Rev. 1959;39(2):183–238. doi: 10.1152/physrev.1959.39.2.183. [DOI] [PubMed] [Google Scholar]
- 10.Bardt TF, Unterberg AW, Hartl R, Kiening KL, Schneider GH, Lanksch WR. Monitoring of brain tissue PO2 in traumatic brain injury: effect of cerebral hypoxia on outcome. Acta Neurochir Suppl. 1998;71:153–156. doi: 10.1007/978-3-7091-6475-4_45. [DOI] [PubMed] [Google Scholar]
- 11.Hemphill JC, 3rd, Morabito D, Farrant M, Manley GT. Brain tissue oxygen monitoring in intracerebral hemorrhage. Neurocrit Care. 2005;3(3):260–270. doi: 10.1385/NCC:3:3:260. [DOI] [PubMed] [Google Scholar]
- 12.Metzger A, Rees J, Kwon Y, et al. Intrathoracic pressure regularion improves cerebral perfusion and cerebral blood flow in a porcine model of brain injury. Shock. 2017;44:96–102. doi: 10.1097/SHK.0000000000000314. [DOI] [PubMed] [Google Scholar]
- 13.Kurita T, Kawashima S, Morita K, Nakajima Y. Use of a short acting B1 blocker during endotoxemia may reduce cerebral tissue oxygenation if hemodynamics are depressed by a decrease in heart rate. Shock. 2017;47:765–771. doi: 10.1097/SHK.0000000000000795. [DOI] [PubMed] [Google Scholar]
- 14.Vogt N, Herden C, Roeb E, Roderfeld M, Eschbach D, Steinfeldt T, Wulf H, Ruchholtz S, Uhl E, Schöller K. Cerebral alterations following experimental multiple trauma and hemorrhagic shock. Shock. 2018;49:164–173. doi: 10.1097/SHK.0000000000000943. [DOI] [PubMed] [Google Scholar]



